Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Sugiyama T, et al. Among authors: isonishi s. J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11. J Clin Oncol. 2016. PMID: 27400948 Clinical Trial.
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Among authors: isonishi s. Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767092 Clinical Trial.
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Among authors: isonishi s. Lancet Oncol. 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948349 Clinical Trial.
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I. Murakami R, et al. Among authors: isonishi s. Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8. Gynecol Oncol. 2019. PMID: 30853361 Clinical Trial.
Pathology-oriented treatment strategy of malignant ovarian tumor in pregnant women: analysis of 41 cases in Japan.
Morikawa A, Ueda K, Takahashi K, Fukunaga M, Iwashita M, Kobayashi Y, Takechi K, Umezawa S, Terauchi F, Kiguchi K, Aoki D, Nomura H, Yoshikawa H, Satoh T, Jobo T, Fujiwara H, Takei Y, Kamoi S, Terao Y, Isonishi S. Morikawa A, et al. Among authors: isonishi s. Int J Clin Oncol. 2014 Dec;19(6):1074-9. doi: 10.1007/s10147-014-0669-3. Epub 2014 Feb 18. Int J Clin Oncol. 2014. PMID: 24534911
92 results